{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:20:53Z","timestamp":1761016853013},"reference-count":119,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.atherosclerosis.2010.08.045","type":"journal-article","created":{"date-parts":[[2010,8,20]],"date-time":"2010-08-20T10:28:11Z","timestamp":1282300091000},"page":"11-19","source":"Crossref","is-referenced-by-count":24,"title":["Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: A systematic review and metaanalysis"],"prefix":"10.1016","volume":"214","author":[{"given":"George","family":"Ntaios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Savopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Chatzopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitri","family":"Mikhailidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Hatzitolios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0005","first-page":"111","article-title":"Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis","volume":"56","author":"McCully","year":"1969","journal-title":"Am J Pathol"},{"issue":"October 16","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0010","first-page":"2015","article-title":"Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis","volume":"288","year":"2002","journal-title":"JAMA"},{"issue":"7 Suppl","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0015","first-page":"S53","article-title":"Low-Dose folic acid supplementation decreases plasma homocysteine concentrations: a randomised trial","volume":"52","author":"Brouwer","year":"2000","journal-title":"Indian Heart J"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0020","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/S0735-1097(99)00469-6","article-title":"Folic acid improves arterial endothelial function in adults with hyperhomocystinemia","volume":"34","author":"Woo","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2010.08.045_bib0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijcard.2009.01.023","article-title":"The effect of folic acid supplementation on carotid intima-media thickness in patients with cardiovascular risk: A randomized, placebo-controlled trial","volume":"143","author":"Ntaios","year":"2010","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0030","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1365-2141.1999.01780.x","article-title":"Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction","volume":"107","author":"Constans","year":"1999","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0035","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1001\/jama.281.22.2113","article-title":"Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins","volume":"281","author":"Nappo","year":"1999","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0040","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/STROKEAHA.108.526798","article-title":"B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial","volume":"40","author":"Hodis","year":"2009","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0045","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jama.291.5.565","article-title":"Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial","volume":"291","author":"Toole","year":"2004","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0050","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMoa055227","article-title":"Homocysteine lowering and cardiovascular events after acute myocardial infarction","volume":"354","author":"Bonaa","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0055","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/01.CIR.103.7.919","article-title":"Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE)","volume":"103","author":"Lonn","year":"2001","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0060","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1001\/jama.298.10.1163","article-title":"Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial","volume":"298","author":"Jamison","year":"2007","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0065","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jama.300.7.795","article-title":"Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial","volume":"300","author":"Ebbing","year":"2008","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0070","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1001\/jama.299.17.2027","article-title":"Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial","volume":"299","author":"Albert","year":"2008","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0075","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1001\/jama.2008.835","article-title":"Lowering homocysteine with B vitamins in patients with coronary artery disease","volume":"300","author":"Ntaios","year":"2008","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0080","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart Lung, and Blood Institute Scientific Statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2006.09.032","article-title":"Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies","volume":"49","author":"Gami","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.atherosclerosis.2005.01.035","article-title":"Beta blocker effects on plasma homocysteine levels in patients with hypertension","volume":"181","author":"Atar","year":"2005","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0095","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/HJH.0b013e328013c581","article-title":"Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease","volume":"25","author":"Campbell","year":"2007","journal-title":"J Hypertens"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0100","first-page":"69","article-title":"Effects of metoprolol and diltiazem on plasma homocysteine levels in patients with isolated coronary artery ectasia","volume":"9","author":"Demir","year":"2009","journal-title":"Anadolu Kardiyol Derg"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0105","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0149-2918(03)80201-1","article-title":"A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus","volume":"25","author":"Derosa","year":"2003","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0167-5273(02)00350-9","article-title":"Effects of a beta-blocker and spironolactone on plasma homocysteine levels","volume":"88","author":"Korkmaz","year":"2003","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00004872-200501000-00019","article-title":"Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension","volume":"23","author":"Muda","year":"2005","journal-title":"J Hypertens"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3317\/jraas.2002.049","article-title":"Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease","volume":"3","author":"Neal","year":"2002","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0125","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.jhh.1002325","article-title":"Effect of ACE inhibitors and beta-blockers on homocysteine levels in essential hypertension","volume":"22","author":"Poduri","year":"2008","journal-title":"J Hum Hypertens"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0130","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/107424840300800206","article-title":"The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study","volume":"8","author":"Rizos","year":"2003","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0135","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.jhh.1001541","article-title":"Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products","volume":"17","author":"Sebekova","year":"2003","journal-title":"J Hum Hypertens"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/meta.2003.50060","article-title":"Antihypertensive treatment and homocysteine concentrations","volume":"52","author":"Westphal","year":"2003","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0145","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.ajkd.2004.11.004","article-title":"Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS)","volume":"45","author":"Ansquer","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0150","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0021-9150(00)00584-0","article-title":"Fenofibrate raises plasma homocysteine levels in the fasted and fed states","volume":"155","author":"Bissonnette","year":"2001","journal-title":"Atherosclerosis"},{"issue":"9148","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(05)77220-2","article-title":"Lipid-lowering drugs and homocysteine","volume":"353","author":"de Lorgeril","year":"1999","journal-title":"Lancet"},{"issue":"9174","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0160","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(99)02153-4","article-title":"Serum homocysteine increases after therapy with fenofibrate or bezafibrate","volume":"354","author":"Dierkes","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0021-9150(00)00766-8","article-title":"Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate","volume":"158","author":"Dierkes","year":"2001","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0170","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.amjcard.2003.12.022","article-title":"Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus","volume":"93","author":"Genest","year":"2004","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0175","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0021-9150(00)00474-3","article-title":"Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia","volume":"154","author":"Giral","year":"2001","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0180","first-page":"243","article-title":"Homocysteine elevation with fibrates: is it a class effect?","volume":"3","author":"Harats","year":"2001","journal-title":"Isr Med Assoc J"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0185","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00125-007-0751-8","article-title":"Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus","volume":"50","author":"Hiukka","year":"2007","journal-title":"Diabetologia"},{"issue":"9168","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0190","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(05)77189-0","article-title":"Lipid-lowering drugs and homocysteine","volume":"353","author":"Landray","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0195","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1538-7933.2004.0584l.x","article-title":"Effect of bezafibrate on plasma homocysteine concentration in men with lower extremity arterial disease","volume":"2","author":"MacCallum","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0200","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0008-6363(01)00382-0","article-title":"Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT)","volume":"52","author":"Malik","year":"2001","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0205","doi-asserted-by":"crossref","first-page":"475","DOI":"10.33549\/physiolres.930856","article-title":"Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates","volume":"55","author":"Mayer","year":"2006","journal-title":"Physiol Res"},{"issue":"5-6","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0210","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00228-003-0616-0","article-title":"Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration","volume":"59","author":"Mayer","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0215","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1016\/S0002-8703(02)00142-4","article-title":"Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia","volume":"144","author":"Melenovsky","year":"2002","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0220","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0002-8703(03)00122-4","article-title":"Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine","volume":"146","author":"Melenovsky","year":"2003","journal-title":"Am Heart J"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0225","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0899-9007(01)00612-8","article-title":"Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy","volume":"17","author":"Stulc","year":"2001","journal-title":"Nutrition"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0230","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/0091270003255920","article-title":"Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia","volume":"43","author":"Milionis","year":"2003","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0235","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0021-9150(02)00417-3","article-title":"Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes","volume":"168","author":"Playford","year":"2003","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10557-006-8374-8","article-title":"The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects","volume":"20","author":"Potaczek","year":"2006","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0245","first-page":"1129","article-title":"Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors","volume":"92","author":"Sebestjen","year":"2004","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0250","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2003.10.003","article-title":"Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis","volume":"172","author":"Syvanne","year":"2004","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0255","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.amjcard.2008.03.076","article-title":"Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus","volume":"102","author":"Terra","year":"2008","journal-title":"Am J Cardiol"},{"issue":"9275","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0260","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(00)05271-5","article-title":"Effects of fenofibrate and gemfibrozil on plasma homocysteine","volume":"358","author":"Westphal","year":"2001","journal-title":"Lancet"},{"issue":"9185","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0265","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(05)75415-5","article-title":"Implication of fibrate therapy for homocysteine","volume":"354","author":"Jonkers","year":"1999","journal-title":"Lancet"},{"issue":"9500","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0270","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0275","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jama.287.5.598","article-title":"Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial","volume":"287","author":"Jula","year":"2002","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0280","first-page":"1273","article-title":"Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia","volume":"98","author":"Bolaman","year":"2006","journal-title":"J Natl Med Assoc"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0285","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0041-1345(02)02768-9","article-title":"Pravastatin treatment-associated reduction in plasma homocysteine in heart-transplanted patients","volume":"34","author":"Capecchi","year":"2002","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0290","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1185\/0300799009117026","article-title":"The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study","volume":"16","author":"Davis","year":"2000","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0295","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0021-9150(00)00567-0","article-title":"Fluvastatin therapy improves microcirculation in patients with hyperlipidaemia","volume":"155","author":"Haak","year":"2001","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0300","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.fertnstert.2008.06.006","article-title":"Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study","volume":"92","author":"Kaya","year":"2009","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0305","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.amjcard.2004.03.052","article-title":"Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia","volume":"94","author":"Lu","year":"2004","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0310","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9150(00)00735-8","article-title":"High-dose simvastin (80mg\/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia","volume":"155","author":"Luftjohann","year":"2001","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0315","first-page":"195","article-title":"A pilot study with simvastatin and folic acid\/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)","volume":"10","author":"MacMahon","year":"2000","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0320","first-page":"52","article-title":"Effects of fluvastatin on homocysteine and serum lipids in kidney allograft recipients","volume":"7","author":"Malyszko","year":"2002","journal-title":"Ann Transplant"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0325","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/089686080302300308","article-title":"Influence of simvastatin on aspects of thrombogenesis in CAPD pa*ti*ents","volume":"23","author":"Malyszko","year":"2003","journal-title":"Perit Dial Int"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0330","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/000331970505600510","article-title":"Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?","volume":"56","author":"Milionis","year":"2005","journal-title":"Angiology"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0335","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0021-9150(02)00318-0","article-title":"Elisaf M. Statins and homocysteine","volume":"166","author":"Miltiadous","year":"2003","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0340","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/archinte.167.12.1262","volume":"167","author":"Nanayakkara","year":"2007","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0345","doi-asserted-by":"crossref","first-page":"c128","DOI":"10.1159\/000074838","article-title":"Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis","volume":"95","author":"Navarro","year":"2003","journal-title":"Nephron Clin Pract"},{"issue":"2-3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.vph.2007.05.001","article-title":"Coronary reactivity, homocysteine and methylenetetrahydrofolate reductase gene variation in young men during pravastatin therapy","volume":"47","author":"Nieminen","year":"2007","journal-title":"Vascul Pharmacol"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0355","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.freeradbiomed.2004.07.019","article-title":"Antioxidant effect of simvastatin is not enhanced by its association with alpha-tocopherol in hypercholesterolemic patients","volume":"37","author":"Pereira","year":"2004","journal-title":"Free Radic Biol Med"},{"issue":"15","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0360","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.CIR.0000014447.06099.FB","article-title":"Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events","volume":"105","author":"Ridker","year":"2002","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0365","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/BF03345621","article-title":"Effect of statins on soluble CD40 ligand in hypercholesterolemic Type 2 diabetic patients","volume":"31","author":"Santini","year":"2008","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0370","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0002-9149(01)02257-3","article-title":"Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia","volume":"89","author":"Sasaki","year":"2002","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0375","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/jwh.2005.14.154","article-title":"The effect of hormone replacement therapy and simvastatin on plasma homocysteine","volume":"14","author":"Sbarouni","year":"2005","journal-title":"J Womens Health (Larchmt)"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0380","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000093200","article-title":"Efficacy and safety of fluvastatin-extended release in hypercholesterolemic patients: morning administration is equivalent to evening administration","volume":"106","author":"Scharnagl","year":"2006","journal-title":"Cardiology"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0385","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1053\/meta.2002.35584","article-title":"Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial","volume":"51","author":"Vigna","year":"2002","journal-title":"Metabolism"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0390","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"issue":"6 Pt 1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0395","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0002-8703(99)70073-6","article-title":"Niacin treatment increases plasma homocyst(e)ine levels","volume":"138","author":"Garg","year":"1999","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0400","doi-asserted-by":"crossref","first-page":"E540","DOI":"10.1152\/ajpendo.2001.280.3.E540","article-title":"Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production","volume":"280","author":"Wang","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0405","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0022-3476(96)70188-9","article-title":"Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia","volume":"129","author":"Tonstad","year":"1996","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0410","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2710.2006.00756.x","article-title":"Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome","volume":"31","author":"Derosa","year":"2006","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0415","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1177\/147323000503300303","article-title":"Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial","volume":"33","author":"Derosa","year":"2005","journal-title":"J Int Med Res"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0420","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/00365519709084603","article-title":"Metformin increases total serum homocysteine levels in non-diabetic male patients with coronary heart disease","volume":"57","author":"Carlsen","year":"1997","journal-title":"Scand J Clin Lab Invest"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0425","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/00016340600855946","article-title":"Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome","volume":"86","author":"Carlsen","year":"2007","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0430","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0168-8227(03)00057-3","article-title":"Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin","volume":"60","author":"Derosa","year":"2003","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0435","first-page":"143","article-title":"Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin","volume":"17","author":"Derosa","year":"2004","journal-title":"Diabetes Nutr Metab"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0440","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.2169\/internalmedicine.46.0320","article-title":"Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial","volume":"46","author":"Derosa","year":"2007","journal-title":"Intern Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0445","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijgo.2008.11.039","article-title":"Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome","volume":"105","author":"Haydardedeoglu","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0450","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/humrep\/deh700","article-title":"Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study","volume":"20","author":"Kilicdag","year":"2005","journal-title":"Hum Reprod"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0455","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2265.2007.02985.x","article-title":"The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome","volume":"67","author":"Sahin","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0460","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jdiacomp.2005.10.005","article-title":"Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus","volume":"21","author":"Sahin","year":"2007","journal-title":"J Diabetes Complications"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0465","first-page":"1236","article-title":"The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension","volume":"54","author":"Sarafidis","year":"2005","journal-title":"An open-label observational study. Metabolism"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0470","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.fertnstert.2006.11.071","article-title":"Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome","volume":"88","author":"Schachter","year":"2007","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0475","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.atherosclerosis.2005.08.012","article-title":"Effect of rosiglitazone on homocysteine and creatinine levels in patients with type 2 diabetes","volume":"183","author":"Stulc","year":"2005","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0480","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1055\/s-2002-23489","article-title":"Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome","volume":"110","author":"Vrbikova","year":"2002","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0485","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-2796.2003.01213.x","article-title":"Effects of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial","volume":"254","author":"Wulffele","year":"2003","journal-title":"J Intern Med"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0490","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1093\/humrep\/dei258","article-title":"The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome","volume":"20","author":"Yilmaz","year":"2005","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0495","first-page":"99","article-title":"Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels","volume":"3","author":"Dierkes","year":"2007","journal-title":"Vasc Health Risk Manag"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0500","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jn\/127.1.117","article-title":"Vitamin B-6 normalizes the altered sulfur amino acid status of rats fed diets containing pharmacological levels of niacin without reducing niacin's hypolipidemic effects","volume":"127","author":"Basu","year":"1997","journal-title":"J Nutr"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0505","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/08037050213758","article-title":"Adrenergic activity and left ventricular mass in patients with essential hypertension","volume":"11","author":"Wocial","year":"2002","journal-title":"Blood Press"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0510","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1046\/j.1471-4159.1997.68062386.x","article-title":"beta-Adrenergic stimulation promotes homocysteic acid release from astrocyte cultures: evidence for a role of astrocytes in the modulation of synaptic transmission","volume":"68","author":"Do","year":"1997","journal-title":"J Neurochem"},{"issue":"8 Pt 1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0515","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0895-7061(99)00058-8","article-title":"Homocysteine levels in hypertensive patients with a history of cardiac or cerebral atherothrombotic events","volume":"12","author":"Sharabi","year":"1999","journal-title":"Am J Hypertens"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0520","first-page":"253","article-title":"Homocysteine plasma levels are independently associated with insulin resistance in normal weight, overweight and obese pre-menopausal women","volume":"14","author":"De Pergola","year":"2001","journal-title":"Diabetes Nutr Metab"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0525","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00228-006-0176-1","article-title":"Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients","volume":"62","author":"Fogari","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0530","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4065\/80.10.1270","article-title":"Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study","volume":"80","author":"Foley","year":"2005","journal-title":"Mayo Clin Proc"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0535","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.2337\/diacare.23.9.1227","article-title":"Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin","volume":"23","author":"Bauman","year":"2000","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0540","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.acvd.2009.07.002","article-title":"The controversial role of B-vitamins in cardiovascular risk: An update","volume":"102","author":"Ntaios","year":"2009","journal-title":"Arch Cardiovasc Dis"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0545","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11695-008-9691-8","article-title":"Decrease in serum protein carbonyl groups concentration and maintained hyperhomocysteinemia in patients undergoing bariatric surgery","volume":"19","author":"Sledzinski","year":"2009","journal-title":"Obes Surg"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0550","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1210\/jc.2006-0944","article-title":"Metabolic syndrome: a solution in search of a problem","volume":"92","author":"Ferrannini","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0555","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1463-1326.2004.00409.x","article-title":"The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study","volume":"7","author":"Athyros","year":"2005","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0560","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1185\/03007990902810999","article-title":"Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study","volume":"25","author":"Athyros","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0565","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1185\/030079904X5599","article-title":"Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study","volume":"20","author":"Athyros","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0570","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.nrl.0000253066.85963.aa","article-title":"Vitamins and stroke: the homocysteine hypothesis still in doubt","volume":"14","author":"Ntaios","year":"2008","journal-title":"Neurologist"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0575","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1517\/14656566.8.14.2267","article-title":"Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?","volume":"8","author":"Athyros","year":"2007","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0580","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/138945007780058933","article-title":"Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels","volume":"8","author":"Athyros","year":"2007","journal-title":"Curr Drug Targets"},{"issue":"14","key":"10.1016\/j.atherosclerosis.2010.08.045_bib0585","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2174\/156802608785849003","article-title":"Molecule of the Month. TREDAPTIVE (nicotinic acid\/laropiprant): a new lipid-modifying therapy for the treatment of LDL-C, HDL-C and triglycerides","volume":"8","author":"Felts","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.atherosclerosis.2010.08.045_bib0590","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2174\/157016106777698450","article-title":"Definitions of metabolic syndrome: Where are we now?","volume":"4","author":"Daskalopoulou","year":"2006","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2010.08.045_bib0595","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1185\/030079905X53333","article-title":"The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions","volume":"21","author":"Athyros","year":"2005","journal-title":"Curr Med Res Opin"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915010006842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915010006842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T22:50:32Z","timestamp":1685746232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915010006842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0021915010006842"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.08.045","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}